Organisation paid for research Program year 2023 Source: CMS Open Payments

Chicago Eye Specialists

Neither a doctor nor a teaching hospital

Research payments

$74,184

44 payments

Through program year 2023, Chicago Eye Specialists is reported as receiving $74,184 in research payments, across 44 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $13,168 1
2022 Research $14,365 1
2021 Research $23,878 5
2020 Research $5,991 19
2019 Research $16,782 18

Breakdown

Who paid Research payments · program years 2019–2023
  1. Glaukos Corporation $27,808 19 payments
  2. AbbVie, Inc. $27,533 2 payments
  3. Allergan Inc. $18,843 23 payments
Studies the money was for Research payments · program years 2019–2023
  1. Long-term Safety and Efficacy Extension Trial of Bimatoprost SR $27,533 2 payments
  2. Prospective, Randomized Phase II Study Comparing Two Elution Rates of Glaukos Travoprost Intraocular Implants to Timolol Maleate Ophthalmic Solution, USP, 0.5 $15,128 12 payments
  3. An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $14,365 1 payment
  4. iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval Study $8,194 2 payments
  5. Prospective, Randomized Phase II Study Comparing Two Elution Rates of Glaukos Travoprost Intraocular Implants to Timolol Maleate Ophthalmic Solution, USP, 0.5% $3,826 4 payments
  6. An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $2,165 15 payments
  7. An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patient with Open Angle Glaucoma or Ocular Hypertension $1,208 4 payments
  8. Efficacy and Safety of Bimatoprost Sustained-Release Sr in Patients With Open-Angle Glaucoma Or Ocular Hypertension $1,105 3 payments
  9. A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery $659 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record